Tesaglitazar

Overview

Tesaglitazar is a dual-target PPARα/γ agonist with an EC 50 of 13.4 μM for rat PPARα and 3.6 μM for human PPARα . Tesaglitazar affects lipid and glucose metabolism by activating PPARα and PPARγ receptors, and has the potential to improve blood sugar and relieve pain. Tesaglitazar can be used to induce in vivo tumor models and can be used in the study of type 2 diabetes, dyslipidemia, and neuropathic pain.

Application

Products | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > Glucose Metabolism | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Digestive System Disease | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Vitamin D Related/Nuclear Receptor | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Metabolic Disease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > PPAR

Product Information

• Catalog No.: HY-17444
• CAS No.: 251565-85-2
• Molecular Formula: C20H24O7S
• Molecular Weight: 408.47
• Purity: 99.08%
• Storage: -20°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
• Solubility: ≥ 5 mg/mL (12.24 mM); Clear solution
• Availability: In-stock

Source

Original product source